InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
33 hedge funds and large institutions have $6.42M invested in InVivo Therapeutics Holdings Corp in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 12 closing their positions.
11% less funds holding
Funds holding: 37 → 33 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
60% less capital invested
Capital invested by funds: $15.9M → $6.42M (-$9.52M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $25K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
IMS Capital Management
Portland,
Oregon
|
+$154K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$92.2K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$92.2K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$92.2K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$61.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$1.36M |
| 2 |
State Street
Boston,
Massachusetts
|
-$615K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$434K |
| 4 |
ECM
Element Capital Management
New York
|
-$368K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$225K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
51
Paloma Partners
Greenwich,
Connecticut
| – | -$225K | -4 | Closed |
|
|
LP
52
LMR Partners
London,
United Kingdom
| – | -$159K | -3 | Closed |
|
53
William Blair & Company
Chicago,
Illinois
| – | -$159K | -3 | Closed |
|
54
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$61.5K | -2 | Closed |
|
55
HighTower Advisors
Chicago,
Illinois
| – | -$57K | -1 | Closed |
|
56
Creative Planning
Overland Park,
Kansas
| – | -$11K | – | – |
|
NVIV Hedge Fund Activity: Q3 2017 in Review
33 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2017, worth a combined $6.42M — down 60% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NVIV and 8 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was IMS Capital Management, adding an estimated $154K. The largest seller was Legal & General Group, exiting entirely with an estimated $1.36M sold.
- 33 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2017, down from 37 in Q2 2017.
- Funds reported $6.42M of InVivo Therapeutics Holdings Corp stock for Q3 2017, down 60% quarter-over-quarter.
- 8 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2017 and 12 closed out, a net change of -4 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2017 was IMS Capital Management, an estimated $154K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2017 was Legal & General Group, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2017.